Archive for the ‘uk retractions’ Category
An investigation by the University College London has cleared prominent geneticist David Latchman of misconduct, but concluded he has “procedural matters in his lab that required attention.”
The results of the investigation were first reported by the Times Higher Education. We also received a short statement from a UCL spokesperson:
Olivier Voinnet — a plant researcher who was recently suspended for two years from the Centre national de la recherche scientifique (CNRS) after an investigation by
ETH Zurich and CNRS found evidence of misconduct — has issued his second retraction and two more corrections.
PNAS posted the retraction earlier this week for a 2006 article after an inspection of the raw data revealed “errors” in study images. Authors confirmed the issues in some figures and revealed “additional mounting mistakes” in others.
Voinnet has promised to issue retractions and corrections for every study that requires them. These latest notices bring our tally up to nine corrections, two retractions and one Expression of Concern.
The author of “The Economic Effects of Climate Change,” Richard Tol, a professor of economics at the University of Sussex, blamed earlier problems with the paper on “gremlins.” In a notice posted last year, Tol wrote that “minus signs were dropped”; he also added a pair of “overlooked estimates” and several recently published studies.
After the first correction was published, several people contacted the JEP to point out more issues with the paper. Editors worked with Tol and outside researchers to update the paper again.
Here’s some text from the newest correction notice:
The retracted paper, “Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis,” shares the first and last authors with the 2001 paper, in Oncogene, as well as two other co-authors.
Bone anatomists have retracted two papers on primate jawbone structure from the Journal of Anatomy due to “errors in the validation protocol and data,” marking the fourth retraction for one of the authors.
Olga Panagiotopoulou retracted two other papers over the past year, all of which were due to a common methodological problem. As Panagiotopoulou — who completed the work in the UK, before joining the University of Queensland in Australia in 2013 — explained to us in April,
Upon realizing they had experienced a case of mistaken cell-line identity, the authors of a 2014 Nature paper on lung cancer think “it prudent to retract pending more thorough investigation,” as they explain in a notice published Wednesday.
The problem seems to stem from more than just honest error, according to corresponding author Julian Downward, a scientist at the Francis Crick Institute in the UK.
In a 1,215 word statement, sent to us via the Director of Research Communications and Engagement at Cancer Research UK, which funds Downward’s research, Downward told us the backstory not presented in the journal’s retraction note:
The European Ophthalmic Review has retracted a 2014 article about the macular degeneration drug aflibercept without any explanation.
Here’s the retraction notice, such as it is:
Chemometrics and Intelligent Laboratory Systems, an Elsevier publication, has retracted a 2014 paper by researchers in China and the United Kingdom for data misuse and authorship issues.
The article, “Optimization of fluidized bed spray granulation process based on a multiphase hybrid model,” was purportedly written by Dapeng Niu, of the College of Information Science and Engineering at Northeastern University, in Shenyang, China, Ming Li, of De Montfort University, in Leicester, England, and Fuli Wang, a vice-president at Northeastern.
But Niu apparently didn’t perform any experiments, lifted the data from other sources, and published the paper without his co-authors’ okay.
The Journal of Bone and Joint Surgery has retracted a 2012 paper because of ethical violations, initially flagged by the journal in 2013.
The study, which examined the use of autologous cell therapy in treating Achilles tendinosis, claimed in its abstract to have “conducted a randomized, double-blind study on forty Achilles tendons in thirty-two patients.” Apparently, though, it wasn’t actually a clinical trial but was somehow, according to the retraction notice, “misclassified” as such “in error.”
The problem was originally flagged by the UK’s Medicines and Healthcare products Regulatory Agency, which wrote the journal to tell them that it hadn’t granted ethical approval for the study, as we reported in 2013. At the time, there was a question about whether the lead author had retained records of the results, which is addressed in the retraction notice, signed by editor-in-chief Marc F. Swiontkowski and editor-in-Chief Emeritus Vernon T. Tolo: Read the rest of this entry »